(NP (NP (NN Cortisol) (NN resistance)) (PP (IN in) (NP (VBN acquired) (NN immunodeficiency) (NN syndrome))) (. .))
(S (NP-SBJ (DT This) (NN study)) (VP (VBZ concerns) (NP (CD 9) (NN iv) (NN drug) (NNS abusers)) (PP (IN with) (NP (NP (VBN acquired) (NN immunodeficiency) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NN AIDS)) (-RRB- -RRB-)))) (SBAR (WHNP-50 (WP who)) (S (NP-SBJ (-NONE- *T*-50)) (VP (VBD developed) (NP (NN hypercortisolism)) (PP (IN without) (NP (NP (DT the) (NP-COOD (NP (JJ clinical) (NNS signs)) (CC or) (NP (JJ metabolic) (NNS consequences)))) (PP (IN of) (NP (NN hypercortisolism))))))))) (. .))
(S (NP-SBJ-51 (DT All) (NNS patients)) (VP (VBD were) (VP (VBN characterized) (NP (-NONE- *-51)) (PP (IN by) (NP (NP (DT an) (JJ Addisonian) (NN picture)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN weakness)) (, ,) (NP (NN weight) (NN loss)) (, ,) (NP (NN hypotension)) (, ,) (NP (NN hyponatremia)) (, ,) (CC and) (NP (JJ intense) (JJ mucocutaneous) (NN melanosis))) (-RRB- -RRB-)))))) (. .))
(S (NP-SBJ-52 (NP (DT An) (JJ acquired) (NN form)) (PP (IN of) (NP (NP (JJ peripheral) (NN resistance)) (PP (TO to) (NP (NNS glucocorticoids)))))) (VP (VBD was) (VP (VBN suspected) (NP (-NONE- *-52)))) (. .))
(S (NP-SBJ-53 (PRP We)) (, ,) (ADVP (RB therefore)) (, ,) (VP (VBD examined) (NP (NP (NN glucocorticoid) (NN receptor) (NNS characteristics)) (PP (IN on) (NP (JJ mononuclear) (NNS leukocytes)))) (PP (IN by) (S (NP-SBJ (-NONE- *-53)) (VP (VBG measuring) (NP-COOD (NP (NN -LCB-3H-RCB-dexamethasone) (NN binding)) (CC and) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN dexamethasone))) (PP (IN on) (NP (NP (NN -LCB-3H-RCB-thymidine) (NN incorporation)) (, ,) (SBAR (WHNP-54 (WDT which)) (S (NP-SBJ (-NONE- *T*-54)) (VP (VBZ is) (NP-PRD (NP (CD one)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN glucocorticoid) (NN receptor) (NN activation))))))))))))))))) (. .))
(S (S (NP-SBJ-55 (NN Glucocorticoid) (NN receptor) (NN density)) (VP (VBD was) (VP (VBN increased) (NP-105 (-NONE- *-55)) (PP (IN in) (NP (NP (NP (NN AIDS) (NNS patients)) (PP (IN with) (NP (DT an) (JJ Addisonian) (NN picture)))) (PRN (-LRB- -LRB-) (FRAG (NP (NP (NN group) (CD 1)) (: ;) (NP (QP (CD 16.2) (CC (- +)) (CD 9.4)) (NN (million fmol)) (NNS cells)))) (-RRB- -RRB-)))) (S (NP-SBJ-106 (-NONE- *-105)) (VP (VBN compared) (NP (-NONE- *-106)) (PP (TO to) (NP (NP (NNS values)) (PP (IN in) (NP-COOD (NP (NP (NP (CD 12) (NN AIDS) (NNS patients)) (PP (IN without) (NP (DT an) (JJ Addisonian) (NN picture)))) (PRN (-LRB- -LRB-) (FRAG (NP (NP (NN group) (CD 2)) (: ;) (NP (QP (CD 6.05) (CC (- +)) (CD 2.6)) (NN (million fmol)) (NNS cells)))) (: ;) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR less) (IN than) (CD 0.01)))) (-RRB- -RRB-))) (CC and) (NP (NP (ADJP-COOD (ADJP (NP (NN sex-)) (ADJP (-NONE- *?*))) (CC and) (ADJP (JJ age-matched))) (NNS controls)) (PRN (-LRB- -LRB-) (FRAG (NP (QP (CD 3.15) (CC (- +)) (CD 2.3)) (NN (million fmol)) (NNS cells))) (: ;) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR less) (IN than) (CD 0.01)))) (-RRB- -RRB-))))))))))) (. .)))
(S (NP-SBJ-56 (NP (NP (DT The) (NN affinity)) (PP (IN of) (NP (NN glucocorticoid) (NNS receptors)))) (PRN (-LRB- -LRB-) (NP (NN Kd)) (-RRB- -RRB-))) (VP (VBD was) (ADVP (RB strikingly)) (VP (VP (VBN decreased) (NP (-NONE- *-56))) (PRN (-LRB- -LRB-) (NP-COOD (NP (NP (QP (CD 9.36) (CC (- +)) (CD 3.44)) (NN nM)) (PP (IN in) (NP (NN group) (CD 1)))) (: ;) (NP (NP (QP (CD 3.2) (CC (- +)) (CD 1.5)) (NN nM)) (PP (IN in) (NP (NN group) (CD 2)))) (: ;) (NP (NP (QP (CD 2.0) (CC (- +)) (CD 0.8)) (NN nM)) (PP (IN in) (NP (NNS controls))))) (: ;) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR less) (IN than) (CD 0.01)))) (-RRB- -RRB-)))) (. .))
(S (S (NP-SBJ-57 (NN -LCB-3H-RCB-Thymidine) (NN incorporation)) (VP (VBD was) (VP (VBN decreased) (NP (-NONE- *-57)) (ADVP (RB dose-dependently)) (PP (IN by) (NP-LGS (NN dexamethasone))) (PP (IN in) (NP-COOD (NP (NNS controls)) (CC and) (NP (NNS patients)))))) (: ;)) (S (NP-SBJ-58 (DT the) (NN effect)) (VP (VBD was) (ADVP (RB significantly)) (VP (VP (VBN blunted) (NP (-NONE- *-58)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR less) (IN than) (CD 0.05)))) (-RRB- -RRB-)) (PP (IN in) (NP (NN group) (CD 1) (NNS patients)))) (, ,) (SBAR (WHNP-60 (WDT which)) (S (NP-SBJ (-NONE- *T*-60)) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ (NP (NN activation)) (PP (IN of) (NP (NN glucocorticoid) (NN receptor)))) (VP (VBZ is) (ADJP-PRD (JJ impaired)) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (DT the) (NN glucocorticoid) (NN receptor) (NN abnormality))))))))))))) (. .)))
(S (PP (IN In) (NP (NN conclusion))) (, ,) (NP-SBJ-62 (NP (NN AIDS) (NNS patients)) (PP (IN with) (NP-COOD (NP (NN hypercortisolism)) (CC and) (NP (NP (JJ clinical) (NNS features)) (PP (IN of) (NP (NP (JJ peripheral) (NN resistance)) (PP (TO to) (NP (NNS glucocorticoids))))))))) (VP (VBP are) (VP (VBN characterized) (NP (-NONE- *-62)) (PP (IN by) (NP-LGS (NP (JJ abnormal) (NN glucocorticoid) (NNS receptors)) (PP (IN on) (NP (NNS lymphocytes))))))) (. .))
(S (NP-SBJ (NP (NN Resistance)) (PP (TO to) (NP (NNS glucocorticoids)))) (VP (VBZ implies) (NP (NP (DT a) (JJ complex) (NN change)) (PP (IN in) (NP (NP (JJ immune-endocrine) (NN function)) (, ,) (SBAR (WHNP-63 (WDT which)) (S (NP-SBJ (-NONE- *T*-63)) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ important)) (PP (IN in) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NN immunodeficiency) (NN syndrome))))))))))))) (. .))
